TransCode Therapeutics Inc (RNAZ)
0.72
+0.09
(+13.83%)
USD |
NASDAQ |
May 02, 13:18
TransCode Therapeutics Cash from Investing (TTM): -0.0454M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0454M |
| September 30, 2023 | -0.0245M |
| June 30, 2023 | -0.0199M |
| March 31, 2023 | -0.0439M |
| December 31, 2022 | -0.0616M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.0964M |
| June 30, 2022 | 0.0248M |
| March 31, 2022 | 0.0446M |
| December 31, 2021 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-0.0616M
Minimum
Dec 2022
0.0964M
Maximum
Sep 2022
-0.0033M
Average
-0.0199M
Median
Jun 2023
Cash from Investing (TTM) Benchmarks
| Citius Pharmaceuticals Inc | -- |
| NovaBay Pharmaceuticals Inc | -0.019M |
| Palatin Technologies Inc | 9.293M |
| iBio Inc | 8.285M |
| Theriva Biologics Inc | -0.202M |